Subscribe To
ANNX / Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington's Disease at AAN 2022
ANNX News
By GlobeNewsWire
September 19, 2023
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class o more_horizontal
By Zacks Investment Research
September 8, 2023
Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc. (ANNX)
Annexon, Inc. (ANNX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with s more_horizontal
By Seeking Alpha
July 14, 2023
Annexon: Mixed Results, Overly Strong Market Reaction
ANNX produced mixed results from its GA program. While the primary endpoint was not met, an important functional endpoint saw success. However, the ma more_horizontal
By Zacks Investment Research
May 30, 2023
Annexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy. more_horizontal
By The Motley Fool
May 25, 2023
Why Shares of Annexon Are Plummeting Thursday
Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February. more_horizontal
By GlobeNewsWire
January 4, 2023
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of more_horizontal
By Benzinga
June 7, 2022
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a more_horizontal
By GlobeNewsWire
March 3, 2022
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington's Disease at AAN 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi more_horizontal